BEDFORD, Mass., June 17, 2015 /PRNewswire/ -- Hologic, Inc.
(NASDAQ: HOLX) announced today that David
LaVance has resigned as Chairman of the Company's Board of
Directors, and notified the Board that he will not stand for
re-election at the 2016 Annual Meeting of Stockholders.
Steve MacMillan, Hologic's
President and Chief Executive Officer, has been appointed Chairman
of the Board. In addition, current Director Elaine Ullian, retired President and Chief
Executive Officer of the Boston Medical Center, has been appointed
Lead Independent Director. Ullian has been a member of the
Company's Board since 2007.
"It has been a great honor to contribute to Hologic's growth and
development since 2002," LaVance said. "The Company's future
is bright, so this is the right time for me to transition
leadership to the experienced team that's now in place."
"I'd like to thank David for his many contributions to Hologic
over 13 years of distinguished service, and for his partnership in
building a board and management team capable of delivering
sustainable growth across the company," MacMillan said.
About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal health. With
a unified suite of technologies and a robust research and
development program, Hologic is dedicated to The Science of Sure.
For more information on Hologic, visit www.hologic.com.
Hologic and associated logos are trademarks and/or registered
trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release contains forward-looking information that
involves risks and uncertainties, including statements about the
Company's plans, objectives, expectations and intentions, and
statements regarding the Company's Board of Directors and
management. These forward-looking statements are based on
assumptions made by the Company as of this date and are subject to
known and unknown risks and uncertainties that could cause actual
results to differ materially from those anticipated. These risks
include, but are not limited to, the risk that the Company may not
be able to attract and retain qualified Board members or
executives. These risks are not exhaustive. Other factors
that could adversely affect the Company's business and prospects
are described in the filings made by the Company with the
SEC. The Company expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
such statements presented here to reflect any change in
expectations or any change in events, conditions or circumstances
on which any such statements are based.
Contact
Michael Watts
Vice President, Investor Relations and
Corporate Communications
(858) 410-8588
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hologic-announces-changes-to-board-of-directors-300100516.html
SOURCE Hologic, Inc.